- $1.88bn
- $1.85bn
- $17.20m
- 50
- 20
- 66
- 42
Annual income statement for Mesoblast, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.46 | 10.2 | 7.5 | 5.9 | 17.2 |
| Cost of Revenue | |||||
| Gross Profit | -25.3 | -20.5 | -20.2 | -9.81 | 12.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 92.6 | 84.4 | 70.9 | 75.1 | 99.9 |
| Operating Profit | -85.2 | -74.1 | -63.4 | -69.2 | -82.7 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -99.6 | -91.6 | -82.1 | -88.1 | -102 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -98.8 | -91.3 | -81.9 | -88 | -102 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -98.8 | -91.3 | -81.9 | -88 | -102 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -98.8 | -91.3 | -81.9 | -88 | -102 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.16 | -0.133 | -0.105 | -0.088 | -0.084 |